Medline's stockholders initiate a public offering of 75 million shares, with no proceeds going to Medline.
Quiver AI Summary
Medline Inc. announced that certain affiliated selling stockholders have begun an underwritten public offering of 75 million shares of Medline's Class A common stock, with an option for underwriters to purchase an additional 11.25 million shares. Medline itself is not selling any shares and will not receive proceeds from the offering. The offering is being managed by several financial institutions, including Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan. A registration statement has been filed with the SEC but has not yet become effective, meaning no shares can be sold until it is. The company, headquartered in Northfield, Illinois, is the largest provider of medical-surgical products and aims to support healthcare providers in improving outcomes.
Potential Positives
- Medline's announcement of the public offering highlights significant interest from major financial entities, indicating strong market confidence in the company's future.
- The offering involves a substantial number of shares (75,000,000), which may enhance liquidity for existing shareholders.
- Medline is positioned as a key player in the medical-surgical products market, emphasizing its extensive workforce and global reach in over 100 countries.
Potential Negatives
- The public offering of 75,000,000 shares may indicate a dilution of ownership and could negatively impact existing shareholders' value.
- Medline is not selling any shares and will not receive any proceeds from the offering, which raises concerns about the company's current capital position and reliance on third-party investors.
- The announcement of an offering by major stockholders could signal a lack of confidence in the company’s stock performance, as it may be interpreted as an opportune moment for insiders to liquidate their positions.
FAQ
Who is offering Medline’s Class A common stock?
The offering is made by selling stockholders affiliated with Blackstone, The Carlyle Group, Hellman & Friedman, and the Abu Dhabi Investment Authority.
How many shares of Medline's stock are being offered?
A total of 75,000,000 shares of Medline's Class A common stock are being offered, with an additional option for 11,250,000 shares.
Will Medline receive any proceeds from this offering?
No, Medline is not selling any shares in this offering and will not receive any proceeds.
How can I obtain the preliminary prospectus for the offering?
You can request the preliminary prospectus from Goldman Sachs, Morgan Stanley, BofA Securities, or J.P. Morgan as detailed in the release.
When will the registration statement for the offering become effective?
The registration statement has been filed but has not yet become effective; sales cannot occur until it does.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDLN Insider Trading Activity
$MDLN insiders have traded $MDLN stock on the open market 12 times in the past 6 months. Of those trades, 4 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:
- PRIVATE LTD GIC has made 1 purchase buying 12,586,206 shares for an estimated $364,999,974 and 1 sale selling 10,204,351 shares for an estimated $289,480,090.
- GROUP INC. CARLYLE sold 19,136,333 shares for an estimated $554,953,657
- GROUP VII S1, L.L.C. TC sold 19,136,333 shares for an estimated $554,953,657
- MOZART COINVESTMENT HOLDINGS, L.P. CARLYLE sold 19,136,333 shares for an estimated $554,953,657
- AGGREGATOR II LP MOZART sold 13,462,600 shares for an estimated $381,911,075
- & FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 3 sales selling 6,088,371 shares for an estimated $172,716,735.
- ANDREW J. MILLS purchased 2,586,206 shares for an estimated $74,999,974
- CHARLES N. MILLS has made 2 purchases buying 2,579,310 shares for an estimated $74,799,990 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDLN Hedge Fund Activity
We have seen 197 institutional investors add shares of $MDLN stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CARLYLE GROUP INC. added 215,303,036 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,042,727,512
- H&F CORPORATE INVESTORS X, LTD. added 99,514,069 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,179,590,898
- FMR LLC added 26,354,214 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,106,876,988
- VANGUARD GROUP INC added 18,887,568 shares (+inf%) to their portfolio in Q4 2025, for an estimated $793,277,856
- MORGAN STANLEY added 15,162,060 shares (+inf%) to their portfolio in Q4 2025, for an estimated $636,806,520
- CAPITAL RESEARCH GLOBAL INVESTORS added 14,784,203 shares (+inf%) to their portfolio in Q4 2025, for an estimated $620,936,526
- LONE PINE CAPITAL LLC added 11,716,697 shares (+inf%) to their portfolio in Q4 2025, for an estimated $492,101,274
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDLN Analyst Ratings
Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 01/12/2026
- Bernstein issued a "Outperform" rating on 01/12/2026
- Wolfe Research issued a "Outperform" rating on 01/12/2026
- BTIG issued a "Buy" rating on 01/12/2026
- Barclays issued a "Overweight" rating on 01/12/2026
- Citigroup issued a "Buy" rating on 01/12/2026
To track analyst ratings and price targets for $MDLN, check out Quiver Quantitative's $MDLN forecast page.
$MDLN Price Targets
Multiple analysts have issued price targets for $MDLN recently. We have seen 23 analysts offer price targets for $MDLN in the last 6 months, with a median target of $50.0.
Here are some recent targets:
- Patrick Wood from Morgan Stanley set a target price of $52.0 on 03/02/2026
- Stephen Baxter from Wells Fargo set a target price of $47.0 on 02/27/2026
- Patrick Donnelly from Citigroup set a target price of $60.0 on 02/26/2026
- Sean Dodge from BMO Capital set a target price of $54.0 on 02/26/2026
- Elizabeth Anderson from Evercore ISI Group set a target price of $55.0 on 02/26/2026
- Ryan Halsted from RBC Capital set a target price of $53.0 on 02/26/2026
- Kevin Caliendo from UBS set a target price of $57.0 on 02/26/2026
Full Release
NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 75,000,000 shares of Medline’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock.
Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers, and Blackstone Capital Markets and Carlyle are acting as co-managers for the proposed offering.
The proposed offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at [email protected]; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at [email protected]; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at [email protected] and [email protected].
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar words or phrases that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainty, and changes in circumstances, many of which are beyond our control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor Relations:
Karen King
Global Head Investor Relations
Patrick Flaherty
Director, Investor Relations
(847) 247-7222
[email protected]
Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
[email protected]
Source: Medline Inc.